2-Year Icotrokinra Data Show Sustained Clearance in High-Impact Psoriasis Sites
Key Takeaways
- Two-year Phase 3 ICONIC-TOTAL data showed sustained responses with oral icotrokinra among adults and adolescents with plaque psoriasis involving high-impact sites.
- At Week 112, complete clearance was reported in 60% of patients with scalp psoriasis, 89% with genital psoriasis, and 63% with hand and/or foot psoriasis.
- Nail psoriasis also improved through Week 112, while Johnson & Johnson reported that longer-term safety findings remained consistent with the established study safety profile and identified no new safety signals.
Johnson & Johnson reported 2-year Phase 3 data showing sustained skin clearance with icotrokinra in adults and adolescents aged 12 years or older with plaque psoriasis involving high-impact sites.
The late-breaking ICONIC-TOTAL results were presented at the European Academy of Dermatology and Venereology Congress 2026. The randomized study evaluated once-daily icotrokinra against placebo in patients with at least moderate psoriasis affecting the scalp, genital area, and/or hands and feet; patients receiving placebo transitioned to icotrokinra at Week 16.
Clearance Responses Persist Through Week 112
Among patients treated with icotrokinra, 57% achieved an Investigator’s Global Assessment (IGA) score of 0 or 1 at Week 16, increasing to 67% at Week 24 and 70% at Week 112.
Site-specific assessments at Week 112 showed complete clearance in 60% of patients with scalp psoriasis, based on a scalp-specific IGA score of 0. Complete clearance was reported in 89% of patients with genital psoriasis and 63% of those with psoriasis affecting the hands and/or feet.
Nail outcomes also improved over time. Mean percentage improvement in the modified Nail Psoriasis Severity Index increased from 33% at Week 16 to 62% at Week 52 and 71% at Week 112.
Johnson & Johnson reported that safety findings through Week 112 remained consistent with the established safety profile observed in the clinical development program, with no new safety signals identified.
“Availability of long-term data are vital for informing the treatment of plaque psoriasis including particularly challenging areas of the body where conventional treatments may fall short,” said David M. Lee, MD, PhD, Global Immunology Therapeutic Area Head at Johnson & Johnson.